The company continues to build evidence for the added sensitivity offered by its urine- and blood-based liquid biopsy approach in an effort to engage clinicians.
The current arrangement builds on an existing agreement signed last year that allowed Garvan to use DNAnexus' platform for its genomics activities.
The clinical trial is designed to validate that biomarkers, measured in routine urine tests, effectively predict genetic mutations in drug-metabolizing enzymes.
The company will soon submit its ePlex instrument and respiratory pathogen panel for US Food and Drug Administration clearance.
For the three months ended June 30, Qiagen reported net sales of $334.4 million, exceeding the Wall Street estimate of $326.8 million.
In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.
South African researchers uncover bone cancer in an ancient hominin ancestor.
English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.
Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.